Tuesday, July 5, 2022

Mirvetuximab Soravtansine Displays Promising Efficacy in Platinum-Resistant Ovarian Cancer

 This is an edited version of an article by Kyle Doherty appearing in OncLive, July 2, 2022.

Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options. However, a new option for these patients whose disease harbors a high level of folate receptor α (FRα) may be emerging as the first-in-class antibody-drug conjugate mirvetuximab soravtansine displayed promising antitumor activity, according to results from the phase 3 SORAYA trial (NCT04296890) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. ...

“The results from SORAYA position were mirvetuximab soravtansine to become a practice-changing therapy for patients with platinum-resistant ovarian cancer [that is] high-grade serous and FRα positive, in a place in treatment where patients have very few options,” said Ursula A. Matulonis, MD, in an interview with OncologyLive®.Mirvetuximab soravtansine is a well-tolerated drug for patients who have responses, and those responses are durable. They are deep responses, where we saw complete responses, which is really an unheard-of phenomenon in the treatment of platinum-resistant ovarian cancer.” ...

Based on the data from SORAYA, the FDA accepted and granted priority review to the biologic license application for mirvetuximab soravtansine and is expected to decide by November 28, 2022. To validate the findings, investigators have initiated the randomized phase 3 randomized MIRASOL trial (NCT04209855) vs investigator’s choice chemotherapy. ...

"For our patients with platinum-resistant ovarian cancer and have also received bevacizumab, their option for treatment is single-agent, nonplatinum-based chemotherapy. [This includes] topotecan and gemcitabine. These drugs typically have low response rates—12% or lower—more often than not in the single agents."

"The data that we saw from SORAYA represents a clinically meaningful anticancer activity for this patient population, who, unfortunately, have very few options. This should be a new standard of care for patients with platinum-resistant, high-grade serous ovarian cancer, where there is high FRα expression within the cancer." --Ursula A. Matulonis, MD, Chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute in Boston, Massachusetts.


 This is an edited version of an article by Chris Ryan published 21 June 2022 by The Clearity Foundation.

The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from the dose-expansion portion of the phase 1 Study 101 trial (NCT03386942) presented during the 2022 ASCO Annual Meeting.


“We are encouraged by the clinical safety and efficacy results, as measured by the preliminary antitumor activity observed in patients with platinum-resistant ovarian cancer being treated with each dose of farletuzumab ecteribulin, and with varying levels of folate receptor-alpha [FRα] expression,” Shin Nishio, MD, PhD, lead study author and an associate professor in the Department of Obstetrics and Gynecology at Kurume University School of Medicine in Fukuoka, Japan, stated in a press release.
Farletuzumab ecteribulin is comprised of the humanized anti-FRα monoclonal antibody, farletuzumab, linked to the cytotoxic microtubule inhibitor, eribulin (Halaven). The ADC delivers the eribulin payload into cancer cells that express FRα.“Based on the data from preclinical studies, farletuzumab ecteribulin has the clinical potential to elicit a bystander effect through an enzymatically cleavable linker that releases a toxic payload from the antibody, therefore acting not only on the FRα-positive cancer cells, but also the FRα-negative cancer cells surrounding the FRα-positive cancer cells,” Nishio added. “As the field of targeted therapy continues to evolve, ADCs are anticipated to become a key modality in the treatment of recurrent, platinum-resistant disease.”